Chen Yu-Hsin, Kuo Ko-Lin, Hung Szu-Chun, Hsu Chih-Cheng, Chen Ying-Hwa, Tarng Der-Cherng
Faculty of Medicine, Division of Nephrology, Department of Internal Medicine, Taipei City Hospital, Yang-Ming Branch, Taipei, Taiwan;
Division of Nephrology, Taipei Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation, Taipei, Taiwan;
J Am Soc Nephrol. 2014 Nov;25(11):2669-77. doi: 10.1681/ASN.2013111205. Epub 2014 Apr 24.
The length polymorphism of guanosine thymidine dinucleotide repeats in the heme oxygenase-1 gene promoter is associated with cardiovascular events and mortality in high-risk populations. Experimental data suggest that heme oxygenase-1 protects against kidney disease. However, the association between this polymorphism and long-term risk of CKD in high-risk patients is unknown. We analyzed the allelic frequencies of guanosine thymidine dinucleotide repeats in the heme oxygenase-1 gene promoter in 386 patients with coronary artery disease recruited from January 1999 to July 2001 and followed until August 31, 2012. The S allele represents short repeats (<27), and the L allele represents long repeats (≥27). The primary renal end points consisted of sustained serum creatinine doubling and/or ESRD requiring long-term RRT. The secondary end points were major adverse cardiovascular events and mortality. At the end of study, the adjusted hazard ratios (95% confidence intervals) for each L allele in the additive model were 1.99 (1.27 to 3.14; P=0.003) for the renal end points, 1.70 (1.27 to 2.27; P<0.001) for major adverse cardiovascular events, and 1.36 (1.04 to 1.79; P=0.03) for mortality. With cardiac events as time-dependent covariates, the adjusted hazard ratio for each L allele in the additive model was 1.91 (1.20 to 3.06; P=0.01) for the renal end points. In conclusion, a greater number of guanosine thymidine dinucleotide repeats in the heme oxygenase-1 gene promoter is associated with higher risk for CKD, cardiovascular events, and mortality among patients with coronary artery disease.
血红素加氧酶-1基因启动子中鸟苷胸腺嘧啶二核苷酸重复序列的长度多态性与高危人群的心血管事件及死亡率相关。实验数据表明,血红素加氧酶-1可预防肾脏疾病。然而,这种多态性与高危患者慢性肾脏病的长期风险之间的关联尚不清楚。我们分析了1999年1月至2001年7月招募的386例冠心病患者血红素加氧酶-1基因启动子中鸟苷胸腺嘧啶二核苷酸重复序列的等位基因频率,并随访至2012年8月31日。S等位基因代表短重复序列(<27),L等位基因代表长重复序列(≥27)。主要肾脏终点包括血清肌酐持续翻倍和/或需要长期肾脏替代治疗的终末期肾病。次要终点为主要不良心血管事件和死亡率。在研究结束时,在相加模型中,每个L等位基因的校正风险比(95%置信区间),肾脏终点为1.99(1.27至3.14;P=0.003),主要不良心血管事件为1.70(1.27至2.27;P<0.001),死亡率为1.36(1.04至1.79;P=0.03)。将心脏事件作为时间依赖性协变量,在相加模型中,每个L等位基因的校正风险比,肾脏终点为1.91(1.20至3.06;P=0.01)。总之,血红素加氧酶-1基因启动子中鸟苷胸腺嘧啶二核苷酸重复序列数量越多,与冠心病患者慢性肾脏病、心血管事件及死亡的风险越高相关。